Improved Brain Delivery of Pueraria Flavones Via Intranasal Administration Of Borneol-Modified Solid Lipid Nanoparticles

Wang, Liping; Zhao, Xiao Guang; Du, Junfeng; Liu, Mei; Jiao, Feng; Hu, Kaili

doi:10.2217/nnm-2018-0417

Cited by 40 publications

(13 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since endocytosis of NPs by the BBB endothelial cells seems to be predominantly mediated by receptors, many efforts have been made with SLN surface functionalization to enhance their CNS availability (Ceña and Játiva, 2018;Kuo et al, 2019;Wang et al, 2019), as discussed in Section 2 for the functionalized angiopep-2 NPs to treat glioblastoma multiforme (Kadari et al, 2018).…”

Section: Passage Through the Blood Brain Barrier (Bbb)mentioning

confidence: 99%

Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects

Montoto

Muraca

Ruiz

2020

Front. Mol. Biosci.

300

131

View full text Add to dashboard Cite

Section: Passage Through the Blood Brain Barrier (Bbb)mentioning

confidence: 99%

Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects

Montoto

Muraca

Ruiz

2020

Front. Mol. Biosci.

300

131

View full text Add to dashboard Cite

“…Wang et al [ 75 ] studied the in vitro efficacy of intranasal Pueraria flavone solution, Pueraria flavone-loaded SLN, Pueraria flavone-loaded SLN modified with borneol and Pueraria flavone-loaded SLN modified with borneol and stearic acid. Pueraria flavone is extracted from the Pueraria thoom sonii and Pueraria lobata and is used for the management of CNS diseases, such as Parkinson’s disease and Alzheimer’s disease.…”

Section: Solid Lipid Nanoparticles (Sln) and Nanostructured Lipid Carriers (Nlc) For Nasal Deliverymentioning

confidence: 99%

In Vitro Studies on Nasal Formulations of Nanostructured Lipid Carriers (NLC) and Solid Lipid Nanoparticles (SLN)

et al. 2021

View full text Add to dashboard Cite

The nasal route has been used for many years for the local treatment of nasal diseases. More recently, this route has been gaining momentum, due to the possibility of targeting the central nervous system (CNS) from the nasal cavity, avoiding the blood−brain barrier (BBB). In this area, the use of lipid nanoparticles, such as nanostructured lipid carriers (NLC) and solid lipid nanoparticles (SLN), in nasal formulations has shown promising outcomes on a wide array of indications such as brain diseases, including epilepsy, multiple sclerosis, Alzheimer’s disease, Parkinson’s disease and gliomas. Herein, the state of the art of the most recent literature available on in vitro studies with nasal formulations of lipid nanoparticles is discussed. Specific in vitro cell culture models are needed to assess the cytotoxicity of nasal formulations and to explore the underlying mechanism(s) of drug transport and absorption across the nasal mucosa. In addition, different studies with 3D nasal casts are reported, showing their ability to predict the drug deposition in the nasal cavity and evaluating the factors that interfere in this process, such as nasal cavity area, type of administration device and angle of application, inspiratory flow, presence of mucoadhesive agents, among others. Notwithstanding, they do not preclude the use of confirmatory in vivo studies, a significant impact on the 3R (replacement, reduction and refinement) principle within the scope of animal experiments is expected. The use of 3D nasal casts to test nasal formulations of lipid nanoparticles is still totally unexplored, to the authors best knowledge, thus constituting a wide open field of research.

show abstract

“…There are two main direct pathways of entry into the brain after intranasal administration, namely, the olfactory and the trigeminal pathway. PTF-Bo-SA-SLNs and PTF-Bo-SLNs can be transported directly from the nasal cavity into the brain through the olfactory region of the nasal epithelium and the trigeminal neural region avoiding the BBB ( 60 ). Furthermore, borneol co-modified liposomes loaded with palmitate azidothymidine have been shown to enhance the transportation of drugs to the brain and increase the accumulation of azidothymidine by 3.73-fold, indicating that the addition of 10% borneol enhances the transportation of drugs in the brain by loosening the tight junctions of BBB ( 61 ).…”

Section: Penetration Promoting Effect and Mechanism Of Borneolmentioning

confidence: 99%

Recent Progress on the Synergistic Antitumor Effect of a Borneol-Modified Nanocarrier Drug Delivery System

Xie

et al. 2021

Front. Med.

View full text Add to dashboard Cite

Borneol, a traditional Chinese medicine, can enhance therapeutic efficacy by guiding the active ingredients to the target site. Reportedly, borneol improves the penetration capacity of the nasal, cornea, transdermal, intestinal, and blood-brain barriers. Although nanotechnology dramatically changed the face of oncology by targeting tumor sites, the efficiency of nanoparticles delivered to tumor sites is very low, with only 0.7% of the total particles delivered. Thus, based on the penetration ability and the inhibition drug efflux of borneol, it was expected to increase the targeting and detention efficacy of drugs into tumor sites in nanocarriers with borneol modification. Borneol modified nanocarriers used to improve drug-targeting has become a research focus in recent years, but few studies in this area, especially in the antitumor application. Hence, this review summarizes the recent development of nanocarriers with borneol modification. We focus on the updated works of improving therapeutic efficacy, reducing toxicity, inhibiting tumor metastasis, reversing multidrug resistance, and enhancing brain targeting to expand their application and provide a reference for further exploration of targeting drug delivery systems for solid tumor treatment.

show abstract

Improved Brain Delivery of Pueraria Flavones Via Intranasal Administration Of Borneol-Modified Solid Lipid Nanoparticles

Cited by 40 publications

References 48 publications

Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects

Solid Lipid Nanoparticles for Drug Delivery: Pharmacological and Biopharmaceutical Aspects

In Vitro Studies on Nasal Formulations of Nanostructured Lipid Carriers (NLC) and Solid Lipid Nanoparticles (SLN)

Recent Progress on the Synergistic Antitumor Effect of a Borneol-Modified Nanocarrier Drug Delivery System

Contact Info

Product

Resources

About